New hope for rare adrenal cancer: immunotherapy trial aims to keep disease at bay
NCT ID NCT07085572
Summary
This study is testing if a drug called cemiplimab can help keep advanced adrenal cancer from getting worse in patients whose disease has responded to initial chemotherapy. The goal is to see if this immunotherapy, given as a maintenance treatment, can delay or prevent the cancer from progressing. The trial is enrolling about 31 adults in Italy who have not seen their cancer worsen after their first round of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENAL CORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
S.C. Oncologia - ASST Spedali Civili di Brescia
RECRUITINGBrescia, Brescia, 25123, Italy
Conditions
Explore the condition pages connected to this study.